<section id="safety" class="section">
    <nav class="desktop">
        <a href="" ui-sref="MOA" class="moa">
            <i class="fas fa-atom"></i>
        </a>
        <a href="" ui-sref="CT" class="ct">
            <i class="fas fa-users"></i>
        </a>
        <a href="" ui-sref="EFFICACY" class="efficacy">
            <i class="fas fa-chart-line"></i>
        </a>
        <a href="" ui-sref="SAFETY" class="safety active">
            <i class="fas fa-exclamation-triangle"></i>
        </a>
        <a href="" ui-sref="DOSING" class="dosing">
            <i class="fas fa-prescription"></i>
        </a>
    </nav>
    <main class="dosing-adjustments">
    <div class="top">
        <a href="" ui-sref="LANDING-PAGE"><img src="assets/pfizer-logo.svg" alt="Pfizer Logo"></a>
        <h1>Tofacitinib pcJIA</h1>
    </div>
    <div class="content">
        <a href="" ui-sref="ADVERSE-EVENTS" class="back-btn safety">
            <i class="fas fa-arrow-circle-left"></i>
            <h5 class="safety-header">BACK</h5>
        </a>
        <h3 class="safety-header">AEs OF SPECIAL INTEREST</h3>
        <div class="img-wrapper">
            <img src="assets/safety/safety-2.svg" alt="patients with events" />
        </div>
        <div class="footnotes">
            <p>Phase 3 safety data include full analysis set (pcJIA , jPsA , ERA patients included).</p>
            <ol>
                <li>
                5 mg BID or equivalent weight based lower dose in patients &lt;40 kg; </li>
                <li>Adjudicated events;</li>
                <li>Both mild and monodermatomal , and neither met opportunistic infection criteria; </li>
                <li>Both cases were mild and monodermatomal and neither case met opportunistic infection criteria</li>
                <li>three subjects in the open label run in phase had serious infections: one patient had three SIs: epidural empyema, sinusitis and subperiosteal abscess. One patient had appendicitis and one patient had pneumonia. </li>
                <li>One serious AE of pilonidal cyst repair was coded to surgical procedures instead of infections and was inadvertently not identified as a serious infection. </li>
                <li>appendicitis . Following adjudication, it was determined that the serious AE did not meet</li>
            </ol>
            <p>opportunistic infection criteria; it is included in the table as a serious infection.
                OL=open label; DB=double blind; NMSC=no n m elanoma skin cancer; DVT=deep vein thrombosis; PE=pulmonary embolism; ATE=arterial thromboembolism
                <br>
                Data on file. Pfizer Inc., New York, NY</p>
        </div>
    </div>
    </main>
</div>
<nav class="mobile">
    <a href="" ui-sref="MOA" class="moa">
        <i class="fas fa-atom"></i>
        <h5>MOA</h5>
    </a>
    <a href="" ui-sref="CT" class="ct">
        <i class="fas fa-users"></i>
        <h5>Clinical Trials</h5>
    </a>
    <a href="" ui-sref="EFFICACY" class="efficacy">
        <i class="fas fa-chart-line"></i>
        <h5>Efficacy</h5>
    </a>
    <a href="" ui-sref="SAFETY" class="safety active">
        <i class="fas fa-exclamation-triangle"></i>
        <h5>Safety</h5>
    </a>
    <a href="" ui-sref="DOSING" class="dosing">
        <i class="fas fa-prescription"></i>
        <h5>Dosing</h5>
    </a>
</nav>
</section>